Recruiting
Hereditary optic atrophy
RecruitingStudy on the Safety and Tolerability of STK-002 for Patients with Autosomal Dominant Optic Atrophy
InvestigationalNo placebo
Study on the Safety and Tolerability of STK-002 for Patients with Autosomal Dominant Optic Atrophy
InvestigationalNo placebo
- Disease:Hereditary optic atrophy
- Substances:18‐MER antisense oligonucleotide complementary to OPA1 PRE-mRNA
Countries:
Austria
Austria- Participants:0–17 years · 18–64 years
- Substances:18‐MER antisense oligonucleotide complementary to OPA1 PRE-mRNA
